Trial
NCT05403450
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Taiho Oncology, Inc.
Collaborators
—
Condition
Relapsed/Refractory Peripheral T-cell Lymphoma
Intervention
Tolinapant
Why stopped
ASTX660-03 was closed according to protocol as no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria.
Provenance
Dataset: 2026-07-10 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-09